UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises PT on Medtronic on FY3Q13 Revenue

In a report published Wednesday, BMO Capital Markets reiterated its Outperform rating on Medtronic
MDT
, and raised its price target from $50.00 to $52.00. BMO Capital Markets noted, “Medtronic's FY3Q13 revenue was in line, EPS beat, and management reiterated guidance. In FY3Q13, Medtronic delivered revenue of $4.03B (up 2.8%; up 3.8% ex-fx), in line with the consensus estimate including ICD sales of $654 million that were a bit below the consensus' $668 million (we estimate MDT held share at 44.8% y/y) while other revenue components were either essentially in line or somewhat better than expected (e.g., pacemaker sales were $459 million versus consensus' $448 million). EPS of $0.93 beat our consensus-matching $0.91.” Medtronic closed on Tuesday at $45.80.
Loading...
Loading...
MDT Logo
MDTMedtronic PLC
$89.31-0.47%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
70.28
Growth
57.04
Quality
38.40
Value
25.03
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Comments
Loading...